➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Colorcon
McKinsey
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,724,353

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,724,353 protect, and when does it expire?

Patent 9,724,353 protects ZERBAXA and is included in one NDA.

This patent has thirteen patent family members in eight countries.

Summary for Patent: 9,724,353
Title:Methods for treating intrapulmonary infections
Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
Inventor(s): Chandorkar; Gurudatt A. (Waltham, MA), Huntington; Jennifer A. (Reading, MA), Parsons; Tara (Hanover, MA), Umeh; Obiamiwe C. (Acton, MA)
Assignee: MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:14/512,608
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,724,353

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA   Start Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,724,353

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2848012   Start Trial
China 103945842   Start Trial
Eurasian Patent Organization 028342   Start Trial
Eurasian Patent Organization 201490590   Start Trial
European Patent Office 2753326   Start Trial
European Patent Office 2862569   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Merck
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.